ArticleBMC cancer2017

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

Yong Jin Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.